Human Laboratory Study of Apremilast for Alcohol Use Disorder

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Alcohol Use Disorder, Alcohol Misuse

In brief

Primary: The primary objective of this study is to compare the efficacy of two different maintenance doses of apremilast (tablets) in reducing alcohol craving among subjects with moderate to severe alcohol use disorder (AUD) after two weeks of daily dosing. Secondary: Secondary objectives include evaluation of two different maintenance doses of apremilast compared with matched placebo on other measures of self-reported alcohol consumption, alcohol craving, alcohol-related negative consequences, AUD symptoms, pain, sleep disturbances, depression, anxiety, quality of life, cigarette smoking, other nicotine use, cannabis use, retention in the study, and safety.

Key facts

Study ID

NCT07325266

Run by

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

People needed

100

Starts

2026-04-03

Expected to finish

2027-07-31

Last updated by the study team

2026-05-01

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Contact study site for exclusion criteria

Where it is running

• University of California — Los Angeles, California, United States (enrolling)
• University of Colorado — Aurora, Colorado, United States (enrolling)
• University of Virginia — Charlottesville, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.